MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [01/16/2026 13:20 PST] MAIA Biotechnology, Inc. (NYSE:maia), Up By 100% ($1.64) After BUYINS.NET SqueezeTrigger Report Released on Wednesday, January 14th 2026 at a Price of $1.639.
• [01/16/2026 10:29 PST] maia SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [01/14/2026 14:55 PST] maia SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.